Efficacy of Sofosbuvir and Ledipasvir in Comparison to Sofosbuvir and Daclatasvir in Management of Egyptian Chronic Hepatitis C Patients

In Egypt, the prevalence of hepatitis C virus (HCV) antibodies is the highest worldwide by 7.6%. Applying efficient treatment protocol on large scale could decrease HCV prevalence as well as disease burden.The aim of this study is to compare the efficacy of Sofosbuvir plus ledipasvir versus Sofosbuvir plus daclatasvir in management of chronic hepatitis C Egyptian patients with either easy to treat (naive patients with Child score A5)or difficult to treat (interferon experienced).